The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies
Phase 1
Terminated
- Conditions
- Advanced Malignancies
- Registration Number
- NCT00468260
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
To evaluate the effects of patupilone on the pharmacokinetics of warfarin in patients with advanced malignancies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Safety Tolerability Potential activity of patupilone once every 21 days in patients that completed the core study
- Secondary Outcome Measures
Name Time Method Objective response and tumor evaluation assessed by response evaluation criteria in solid tumors (RECIST)